Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
Active, not recruiting · NCT03573648 · Registry updated 2026-09-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT03573648 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Allegheny Health Network | 6 |
| National Institutes of Health (NIH) | 667 |
| Pfizer | 431 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Allegheny Health Network | Pittsburgh | United States | 13 |
| Sibley Memorial Hospital | Washington D.C. | United States | 121 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | United States | 24 |
| University of Alabama at Birmingham | Birmingham | United States | 193 |